Study type: Human research · Status: Verified against declared source
Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial.
Archives of dermatological research · 2023
Study scale: Wound healing in DFU (diabetic foot ulcer) has prolonged inflammation phase and defective granulation tissue formation.
Abstract only: Open source record
Product or molecular entity relationships
- LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.
Plain-language verified summary
Question
LL-37 is a promising treatment for chronic wounds because of its antibiofilm property and because it is part of host cells which act simultaneously to eradicate causative bacteria.
Methods
The validation test was conducted to prove that the HPLC (high-performance liquid chromatography) method could provide consistent measurement results of LL-37 levels in accordance with the established and well-documented specifications based on AOAC (Association of Official Analytical Chemists) and ICH (International Conference on Harmonization) criteria [25, 26].
Scale or participants
Wound healing in DFU (diabetic foot ulcer) has prolonged inflammation phase and defective granulation tissue formation.
Key findings
Wound healing in DFU (diabetic foot ulcer) has prolonged inflammation phase and defective granulation tissue formation.
Limitations and uncertainty
Wound healing in DFU (diabetic foot ulcer) has prolonged inflammation phase and defective granulation tissue formation.
Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.